CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Next Revolution In MedicineForbes • 01/11/21
Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical TrialGlobeNewsWire • 01/11/21
Genetics Stocks Pop After Intellia Offers Update For Gene-Editing DrugsInvestors Business Daily • 01/07/21
Domino's, FedEx, Lockheed, Roku and More of Tuesday Afternoon's Analyst Calls24/7 Wall Street • 01/07/21
Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/21
Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking TodayThe Motley Fool • 12/29/20
Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestors Business Daily • 12/21/20
Editas surges 50% as ARK founder Cathie Wood sees genomic stocks driving returns for the next 5 years (EDIT)Business Insider • 12/21/20
Editas Medicine Announces Submission of IND Application for EDIT-301 with the FDAGlobeNewsWire • 12/09/20